{"id":5164,"date":"2018-05-17T12:15:36","date_gmt":"2018-05-17T10:15:36","guid":{"rendered":"https:\/\/www.sequanamedical.com\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/"},"modified":"2022-06-30T15:24:25","modified_gmt":"2022-06-30T13:24:25","slug":"sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/","title":{"rendered":"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites."},"content":{"rendered":"<p>Zurich, SWITZERLAND \u2013 16. May 2018 &#8212; Sequana Medical AG (\u201cSequana Medical\u201d), a commercial stage medical device company and an innovator in the management of liver disease &#038; malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018.  First, the inclusion of <strong>alfa<\/strong>pump\u00ae in the EASL  Clinical Practice Guidelines for the management of patients with decompensated cirrhosis  was announced, and secondly, the study by Macdonald et al reported that the physical component of health-related quality of life (\u201cQoL\u201d) is an independent predictor of mortality in refractory ascites patients.<\/p>\n<p>The EASL clinical practice guidelines refer to two <strong>alfa<\/strong>pump\u00ae multicentre safety and efficacy studies demonstrating a significant reduction of the number and volume of paracentesis in patients with advanced cirrhosis and refractory ascites by <strong>alfa<\/strong>pump\u00ae. In addition, a multicentre randomised controlled trial in patients with refractory ascites is cited, showing a reduction in the median number of paracentesis per month by 85 % with respect to large volume paracentesis  . Nutritional parameters and quality of life were also significantly improved in patients treated with the <strong>alfa<\/strong>pump\u00ae system in this study.<\/p>\n<p>The importance of quality of life for patients with severe ascites was demonstrated in a study by Stewart Macdonald et al. The analysis of data of 405 cirrhotic patients with severe ascites that were enrolled in a randomized controlled trial show that the physical component of the health-related quality of life is an independent predictor of mortality in these patients. According to this study, a poor physical component of quality of life in patients with severe ascites is associated with increased mortality.  <\/p>\n<p>The multicentre, randomized controlled trial (published in the Journal of Hepatology and Quality of Life Research) and the MOSAIC study (presented at the Annual Meeting of the American Association for the Study of Liver Diseases Annual Meeting 2017) both reported that the <strong>alfa<\/strong>pump\u00ae demonstrated a clinically meaningful improvement of health-related quality of life in patient with refractory ascites. <\/p>\n<p>\u201cIt is exciting to see the scientific community has been evaluating the growing clinical evidence that is currently available for the <strong>alfa<\/strong>pump\u00ae. The collaboration with many clinicians to demonstrate the benefits of the <strong>alfa<\/strong>pump\u00ae in multiple studies with different designs (from randomized controlled trials to \u201creal world\u201d post-market studies) has been a strong focus for us during the last years\u201d said Gijs Klarenbeek, Consulting Chief Medical Officer of Sequana Medical. \u201cIt is very rewarding to see this is now leading to the <strong>alfa<\/strong>pump\u00ae now being included in the EASL clinical practice guidelines.\u201d<\/p>\n<p>\u201cWe are delighted that the <strong>alfa<\/strong>pump\u00ae is included in the EASL clinical practice guidelines.  This important step for the <strong>alfa<\/strong>pump\u00ae and Sequana Medical is a clear recognition of the extensive work that has been done in partnership with our partners in the clinical community to demonstrate the benefits that the <strong>alfa<\/strong>pump\u00ae brings to this important patient group\u201d said Ian Crosbie, Chief Executive Officer of Sequana Medical. \u201cThe publication by Macdonald et al is exciting as it demonstrates the link between physical component of quality of life and mortality in cirrhotic patients with severe ascites.  We have repeatedly demonstrated that the <strong>alfa<\/strong>pump\u00ae improves quality of life, one of the key clinical objectives in the management of these patients.\u201d <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zurich, SWITZERLAND \u2013 16. May 2018 &#8212; Sequana Medical AG (\u201cSequana Medical\u201d), a commercial stage medical device company and an innovator in the management of liver disease &#038; malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump\u00ae [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-5164","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Zurich, SWITZERLAND \u2013 16. May 2018 &#8212; Sequana Medical AG (\u201cSequana Medical\u201d), a commercial stage medical device company and an innovator in the management of liver disease &#038; malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump\u00ae [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-17T10:15:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-30T13:24:25+00:00\" \/>\n<meta name=\"author\" content=\"luca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/\"},\"author\":{\"name\":\"luca\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/a2c1f689fbb4e32a5d100b1fea0ea29a\"},\"headline\":\"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites.\",\"datePublished\":\"2018-05-17T10:15:36+00:00\",\"dateModified\":\"2022-06-30T13:24:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/\"},\"wordCount\":556,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/\",\"name\":\"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2018-05-17T10:15:36+00:00\",\"dateModified\":\"2022-06-30T13:24:25+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/a2c1f689fbb4e32a5d100b1fea0ea29a\",\"name\":\"luca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"caption\":\"luca\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical","og_description":"Zurich, SWITZERLAND \u2013 16. May 2018 &#8212; Sequana Medical AG (\u201cSequana Medical\u201d), a commercial stage medical device company and an innovator in the management of liver disease &#038; malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump\u00ae [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2018-05-17T10:15:36+00:00","article_modified_time":"2022-06-30T13:24:25+00:00","author":"luca","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/"},"author":{"name":"luca","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/a2c1f689fbb4e32a5d100b1fea0ea29a"},"headline":"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites.","datePublished":"2018-05-17T10:15:36+00:00","dateModified":"2022-06-30T13:24:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/"},"wordCount":556,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/","name":"Sequana Medical announces inclusion of alfapump\u00ae in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2018-05-17T10:15:36+00:00","dateModified":"2022-06-30T13:24:25+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-inclusion-alfapump-easl-clinical-practice-guidelines-presentation-study-demonstrating-physical-component-qol-predictor-mortality-refractory-asc\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/a2c1f689fbb4e32a5d100b1fea0ea29a","name":"luca","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","caption":"luca"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/5164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=5164"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/5164\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=5164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=5164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=5164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}